Alfresa Holdings Reports Mixed First Quarter Results Amid Revenue Gains and Cost Pressures

TOKYO, Aug 05 (Pulse News Wire) – Alfresa Holdings Corporation (2784.T) reported mixed results for the quarter ending June 30, 2026. Revenue increased to ¥789.0 billion (up 4.1%), but operating profit was ¥5.596 billion (down -19.6%).

Net profit attributable to parent shareholders was ¥6.088 billion (down -20.5%). The healthcare distribution segment saw revenue growth due to higher sales of diabetes treatments and medical devices, reaching 7,098 billion yen (up 4.6%) despite cost pressures from recent price adjustments and rising logistics expenses. However, the pharmaceutical manufacturing division struggled, posting lower revenues and reporting an lower operating profit of 6 billion yen amid restructuring efforts and investment costs.

Alfresa also noted the integration of ArkMS, a subsidiary involved in contract research organization services, which contributed to overall losses in the other operations category. The company expects continued challenges in managing costs while expanding service offerings across various segments. For the fiscal year ending March 2027, Alfresa forecasts stable performance with projected revenues of ¥3.14 trillion (up 1.3%) and net profit of -5.3% million yen (up ¥20.80 billion%).